growth in business and value at one year of the IPO

Pisa, July 18, 2018 – PharmaNutra SPA (Aim Italy – Ticker PHN), a leading company in the sector of iron nutrient supplements, today famous On the first anniversary of the IPO. Borsa, which took place exactly on July 18, 2017. An intense year, in which the market showed great interest and appreciation for the Company founded in 2003 by brothers Andrea and Roberto Lacorte, current president and vice president of the Group. The figures show a steady growth: the value of the PharmaNutra share has indeed increased from 10 euros on the day of introduction to 15.05 euros on July 17, 2018 *, while the capitalization of the Company grew by more than 48%, from 89 million euros to 145.7 million euros as of July 17, 2018 **. The evolution of the turnover, which recorded in the last 12 months a significant double-digit growth (+ 15.3% compared to 2016), both in the Italian and international markets , reflects a constant development of the Group's business. If we consider the period January-May 2018, compared to the same interval of 2017, sales in Italy increased by 20%, while at the international level, the increase was 48%. These results were mainly supported by three key growth drivers for the development of the PharmaNutra business: the development of innovative technologies with the launch of new products, the strengthening of the sales network in Italy and the internationalization of the Group. A path that PharmaNutra is ready to face with pbadion and enthusiasm, maintaining its precise identity based on clear and shared values. Pharmanutra's president, Andrea Lacorte, commented: "The balance of these 12 months on the stock market is very positive: the performance of the title, since the beginning of the year, has shown a much larger increase than the FTSE indices. AIM and FTSE MIB., Confirming the market's appreciation of what has been achieved so far. Looking to the future, there's more than just a solid foundation for continuing to grow: we We have a number of projects under way and a lot of research that is already promising, as well as ideas that are ready to be implemented.We are the first to invest in PharmaNutra, so we know what the expectations of investors are and we hope that markets will continue to appreciate our work. " "PharmaNutra is perfectly suited to the procedures governing a publicly traded company and today, thanks to listing, is more solid, structured and able to continue this growth shared with the market." Attractiveness PharmaNutra's share is attested and confirmed by the entry of new international investors, "adds Roberto Lacorte, Vice President of the Group. * The value is obtained by comparing the subscription price of the convertible bonds issued by the Ipo Challenger 1 pre-reservation company, equal to 10 euros, at the closing date of the stock on July 17, 2018. ** The capitalization figure of Pharmanutra is updated to July 17, 2018 (source: Borsa Italiana) "The obligations and rules introduced with the IPO are nothing revolutionary for us" – adds Roberto Lacorte – "because it is in our DNA to base growth by sharing decisions the most important strategic areas – see the presence of extensive advice on other topics – and broaden participation in the capital to the people we consider important to the growth of the Group. This is the natural evolution of an attitude that is already part of the company. "According to Carlo Volpi, CEO of PharmaNutra, he points out that" the IPO has represented an accelerator of the evolution of the company.One of the goals we set ourselves before entering the stock market was to add external growth to the growth It is only one year since the end of the year, but we are certainly on the right track because the growing international visibility we see will not only attract new investors, but also penetrate new markets. "PharmaNutra SpA Founded and led by President Andrea Lacorte and Vice President Roberto Lacorte, PharmaNutra is a company founded in 2003 that develops unique nutritional supplements and innovative nutritional devices, taking in charge of the whole production process, from raw materials to the finished product. The efficacy of the products is demonstrated by numerous clinical studies, of which 79 published with more than 5000 treated patients. The Group distributes and sells in Italy and abroad. In Italy, the sales activity is ensured by a network of 180 commercial scientific informants serving the medical clbad, also dedicated to the exclusive marketing of Pharmanutra products in the country's pharmacies. The sale abroad is guaranteed in more than 70 countries through 35 partners selected from the best pharmaceutical companies. Pharmanutra is a leader in the production of iron-based nutritional supplements with the SiderAL brand, where it holds important patents on sucrosomal technology. Over the years, the Group has developed a specific strategy in the management and production of intellectual property, based on the integrated management of all components: raw materials, patents, trademarks and clinical evidence. Http://www.PharmaNutra.it For information: PharmaNutra SpA Via Delle Lenze, 216 / b 56122 Pisa Phone +39 050 7846500 Fax +39 050 7846524 [email protected] Nomad & Specialist CFO SIM SpA Via dell & Annunciata 23/4 20121 Milan Tel +39 02 303431 [email protected] Spriano Communication & Partners Press Office Tel +39 02 83635708 Matteo Russo – Cristina Tronconi Mob. +39 347 9834881 +39 346 0477901 [email protected] [email protected]